$OPK Jon Cohen, executive chairman of BioReference Laboratories, part of Opko Health, said his lab would begin running SARS-CoV-2 tests within the next 24 hours, starting with throughput of several hundred tests per day and expanding to "a couple of thousand" per day next week, "and then from there to 5,000 to 10,000 per day."
He said the company would be running the CDC assay along with assays on at least two other platforms and possibly three.
"We're scaling on multiple platforms which are much more automated, with auto-extraction, and a larger number of wells," compared to the testing platforms currently in use, he said.
Cohen said he believed that "within the next couple weeks" BioReference would have the testing capacity it needed to meet demand.
News 
Market Data 
Discover 
